Purchasing price of Nexavar in India is 13501239552 Purchasing Nexavar in India

!: /, : ) This product must be taken under the guidance of a doctor experienced in its use.
< /, ) b !: /, : ) There is currently a lack of randomized controlled clinical study data comparing sorafenib with interventional therapy such as C in patients with advanced hepatocellular carcinoma, so it is still unclear whether this product is comparable to interventional therapy. advantages, and it is unclear whether the use of sorafenib is beneficial to patients who have previously undergone interventional treatment (see [Clinical Trials] item). It is recommended that doctors choose appropriate treatment methods based on comprehensive consideration of the patient's specific conditions.
< /, ) b !: /, : ) Pregnancy: Women of childbearing age should pay attention to contraception during treatment. Women of childbearing potential should be informed of the possible harm to the fetus, including serious malformations (teratogenicity), developmental disorders, and fetal death (embryotoxicity). Sorafenib should be avoided during pregnancy. It can only be used in pregnant women if the benefits of treatment outweigh the possible harm to the fetus.
< /, ) b !: /, : ) Sorafenib has been found to be teratogenic and embryo-fetal toxic (including increased risk of miscarriage and developmental disorders) in animal experiments, and these harmful effects are significantly lower than Appears at clinical doses. Based on the mechanism of sorafenib's inhibition of multiple kinases and the results of animal experiments, it is speculated that taking sorafenib by pregnant women will harm the fetus.
< /, ) b !: /, : ) Breastfeeding women should stop breastfeeding during treatment with sorafenib.
< /, ) b !: /, : ) Skin toxicity: Hand-foot skin reactions and rash are the most common adverse reactions of sorafenib. Rashes and skin reactions of hands and feet are usually grade C to grade and occur more frequently within a few weeks of starting sorafenib. Management of cutaneous toxic reactions includes topical administration to reduce symptoms, temporary discontinuation of the drug, and/or dose adjustment of sorafenib. Permanent discontinuation of sorafenib may be required in patients with severe skin toxicity or prolonged reactions.
< /, ) b !: /, : ) Hypertension: The incidence of hypertension is increased in patients taking sorafenib. Hypertension is mostly mild to moderate, often appears in the early stages after starting to take medication, and can be controlled with conventional antihypertensive drugs. Blood pressure should be monitored regularly and treated according to standard treatment regimens if necessary. Permanent discontinuation of sorafenib should be considered in patients with severe or persistent hypertension or hypertensive crisis despite the use of antihypertensive drugs.
< /, ) b !: /, : ) Bleeding: The chance of bleeding may increase after treatment with sorafenib. Severe bleeding is uncommon. Once bleeding requires treatment, it is recommended to consider permanently discontinuing sorafenib.
< /, ) b !: /, : ) Warfarin: Some patients taking sorafenib and warfarin at the same time may occasionally experience bleeding or elevated R. Patients taking concomitant warfarin should regularly monitor changes in prothrombin time, R value, and pay attention to clinical signs of bleeding.
< /, ) b !: /, : ) Wound healing complications: The effects of taking sorafenib on wound healing have not been formally studied. Patients who require major surgery are advised to suspend sorafenib. There is limited clinical experience in when to re-apply sorafenib to patients after surgery. Therefore, clinical considerations should be made before deciding to use sorafenib again to ensure wound healing.
< /, ) b !: /, : ) Myocardial ischemia and/or myocardial infarction: Incidence of treatment-related myocardial ischemia/myocardial infarction in the sorafenib group during the trial (.%) higher than the placebo group (.%). In the trial, treatment-related myocardial ischemia/myocardial infarction occurred in .% in the sorafenib group and in .% in the placebo group. Patients with unstable coronary artery disease and patients with recent myocardial infarction were not enrolled in either trial. Temporary or permanent discontinuation of sorafenib therapy should be considered in patients who develop myocardial ischemia and/or myocardial infarction.
< /, ) b !: /, : ) Interval prolongation: According to reports, sorafenib can prolong the /c interval and increase the risk of ventricular arrhythmias. In a clinical pharmacology study, patients underwent baseline (treatment